113 related articles for article (PubMed ID: 9726023)
21. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.
Alessandri C; Basili S; Violi F; Ferroni P; Gazzaniga PP; Cordova C
Thromb Haemost; 1994 Sep; 72(3):343-6. PubMed ID: 7855781
[TBL] [Abstract][Full Text] [Related]
22. IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF).
Pastor MD; Nogal A; Molina-Pinelo S; Quintanal-Villalonga Á; Meléndez R; Ferrer I; Romero-Romero B; De Miguel MJ; López-Campos JL; Corral J; García-Carboner R; Carnero A; Paz-Ares L
J Thorac Oncol; 2016 Dec; 11(12):2183-2192. PubMed ID: 27524264
[TBL] [Abstract][Full Text] [Related]
23. Chronic obstructive pulmonary disease among lung cancer-free smokers: The importance of healthy controls.
Karpman MD; Eldridge R; Follis JL; Etzel CJ; Shete S; El-Zein RA
Respir Investig; 2018 Jan; 56(1):28-33. PubMed ID: 29325677
[TBL] [Abstract][Full Text] [Related]
24. Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.
Berg J; Halvorsen AR; Bengtson MB; Taskén KA; Mælandsmo GM; Yndestad A; Halvorsen B; Brustugun OT; Aukrust P; Ueland T; Helland Å
BMC Cancer; 2018 Jul; 18(1):739. PubMed ID: 30005623
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance of Circulatory miRNA-21 as an Efficient Non-Invasive Biomarker for the Screening of Lung Cancer Patients.
Abu-Duhier FM; Javid J; Sughayer MA; Mir R; Albalawi T; Alauddin MS
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2607-2611. PubMed ID: 30256067
[TBL] [Abstract][Full Text] [Related]
26. Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling.
Okano T; Seike M; Kuribayashi H; Soeno C; Ishii T; Kida K; Gemma A
Int J Oncol; 2016 Mar; 48(3):945-52. PubMed ID: 26783151
[TBL] [Abstract][Full Text] [Related]
27. Inhaled corticosteroids in COPD and the risk of lung cancer.
Lee YM; Kim SJ; Lee JH; Ha E
Int J Cancer; 2018 Nov; 143(9):2311-2318. PubMed ID: 29943812
[TBL] [Abstract][Full Text] [Related]
28. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
30. Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors.
De Biasi F; Del Sal G; Hand PH
Int J Cancer; 1989 Mar; 43(3):431-5. PubMed ID: 2784420
[TBL] [Abstract][Full Text] [Related]
31. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.
Wagner PL; Perner S; Rickman DS; LaFargue CJ; Kitabayashi N; Johnstone SF; Weir BA; Meyerson M; Altorki NK; Rubin MA
Am J Clin Pathol; 2009 Oct; 132(4):500-5. PubMed ID: 19762526
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Oxidative Damage and Antioxidant Mechanisms in COPD, Lung Cancer, and Obstructive Sleep Apnea Syndrome.
Sunnetcioglu A; Alp HH; Sertogullarından B; Balaharoglu R; Gunbatar H
Respir Care; 2016 Feb; 61(2):205-11. PubMed ID: 26604330
[TBL] [Abstract][Full Text] [Related]
33. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
[TBL] [Abstract][Full Text] [Related]
35. Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians' health study.
Perera FP; Tang D; Brandt-Rauf P; Santella RM; Mooney LV; Tu YH; Bendkowska I; Bell DA
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1417-9. PubMed ID: 16835348
[No Abstract] [Full Text] [Related]
36. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease.
Deja S; Porebska I; Kowal A; Zabek A; Barg W; Pawelczyk K; Stanimirova I; Daszykowski M; Korzeniewska A; Jankowska R; Mlynarz P
J Pharm Biomed Anal; 2014 Nov; 100():369-380. PubMed ID: 25213261
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
[TBL] [Abstract][Full Text] [Related]
38. PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
Ng Kee Kwong F; Nicholson AG; Pavlidis S; Adcock IM; Chung KF
BMC Cancer; 2018 Dec; 18(1):1238. PubMed ID: 30526542
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer.
Zhang C; Jia Y; Jia Y; Zhang X; Li K
Int J Clin Oncol; 2018 Dec; 23(6):1070-1075. PubMed ID: 30168089
[TBL] [Abstract][Full Text] [Related]
40. [Clinical significance of oncogene product expression in human lung cancer].
Dosaka-Akita H; Harada M; Miyamoto H; Kawakami Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1441-7. PubMed ID: 1331597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
